Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;8(3 Suppl):e31s-7s.
doi: 10.1200/JOP.2012.000548.

Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer

Joseph C Hodges  1 , Yair Lotan, Thomas P Boike, Rhonda Benton, Alyson Barrier, Robert D Timmerman
Affiliations

Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer

Joseph C Hodges et al. J Oncol Pract. 2012 May.

Abstract

Purpose: The purpose of this study is to compare the cost-effectiveness of two external beam radiation therapy techniques for treatment of low- to intermediate-risk prostate cancer: stereotactic body radiation therapy (SBRT) and intensity-modulated radiation therapy (IMRT).

Materials and methods: A Markov decision analysis model with probabilistic sensitivity analysis was designed with the various disease states of a 70-year-old patient with organ-confined prostate cancer to evaluate the cost-effectiveness of two external beam radiation treatment options.

Results: The Monte Carlo simulation revealed that the mean cost and quality-adjusted life-years (QALYs) for SBRT and IMRT were $22,152 and 7.9 years and $35,431 and 7.9 years, respectively. The sensitivity analysis revealed that if the SBRT cohort experienced a decrease in quality of life of 4% or a decrease in efficacy of 6%, then SBRT would no longer dominate IMRT in cost-effectiveness. In fact, with these relaxed assumptions for SBRT, the incremental cost-effectiveness ratio of IMRT met the societal willingness to pay threshold of $50,000 per QALY.

Conclusion: Compared with IMRT, SBRT for low- to intermediate-risk prostate cancer has great potential cost savings for our health care system payers and may improve access to radiation, increase patient convenience, and boost quality of life for patients. Our model suggests that the incremental cost-effectiveness ratio of IMRT compared with SBRT is highly sensitive to quality-of-life outcomes, which should be adequately and comparably measured in current and future prostate SBRT studies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Various disease states of a 70-year-old man with organ-confined prostate cancer. IMRT, intensity-modulated radiation therapy; NED, no evidence of disease; SBRT, stereotactic body radiation therapy.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer facts and figures 2012. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/can....
    1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117–128. - PMC - PubMed
    1. Ollendorf DA, Hayes J, McMahon P, et al. Boston, MA: Institute for Clinical and Economic Review; 2009. Management options for low-risk prostate cancer: A report on comparative effectiveness and value.
    1. Centers for Medicare and Medicaid Services, Medicare Evidence Development and Coverage Advisory Committee. Baltimore, MD: Centers for Medicare and Medicaid Services; 2010. Comparative evaluation of radiation treatments for clinically localized prostate cancer: An update.
    1. Centers for Medicare and Medicaid Services, Medicare Evidence Development and Coverage Advisory Committee. Baltimore, MD: Centers for Medicare and Medicaid Services; 2011. Outcomes of sipuleucel-T therapy.